Corcept Therapeutics to Announce Preliminary Selected Financial Results, Provide Corporate Update and Host Conference Call
Corcept Therapeutics (NASDAQ: CORT) will report its preliminary fourth quarter and full-year 2020 financial results on February 8, 2021. A corporate update will accompany the results, followed by a conference call at 5:00 p.m. ET. Participants can join the call by dialing the provided numbers or by accessing the link for a listen-only mode. Corcept specializes in developing drugs that target cortisol-related disorders, with Korlym® being its flagship product approved for Cushing’s syndrome.
- Scheduled release of preliminary financial results for Q4 and full-year 2020.
- None.
MENLO PARK, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report its preliminary 2020 fourth quarter and full-year financial results and provide a corporate update on February 8, 2021. The company will host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Conference Call Information
To participate, dial 1-833-693-0540 (United States) or 1-661-407-1581 (internationally) approximately 15 minutes before the start of the call. The conference ID number is 9289307.
For access to the call in “listen-only” mode, click this link and provide the requested information. The link will be active 15 minutes prior to the call’s scheduled start time.
About Corcept Therapeutics Incorporated
Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym® was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing’s syndrome. Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol. The company owns extensive United States and foreign intellectual property covering the composition of its selective cortisol modulators and the use of cortisol modulators to treat a variety of serious disorders.
CONTACT:
Christopher S. James, MD
Director, Investor Relations
Corcept Therapeutics
650-684-8725
cjames@corcept.com
www.corcept.com
FAQ
When will Corcept Therapeutics report its financial results for Q4 2020?
What is the significance of the upcoming conference call for CORT?
How can I participate in the Corcept Therapeutics conference call?
What is Corcept Therapeutics known for?
What time is Corcept's conference call?
